PMV Pharmaceuticals reported its full year 2024 financial results and provided a corporate update on March 3, 2025. Enrollment is on track for the Phase 2 pivotal portion of the PYNNACLE clinical trial, evaluating rezatapopt as monotherapy in patients with specific advanced solid tumors, with over 90% of sites activated across multiple regions. Interim analysis data from the PYNNACLE trial is expected in mid-2025. Enrollment has commenced in a Phase 1b study at MD Anderson Cancer Center, evaluating rezatapopt in patients with relapsed or refractory AML/MDS. The company's cash, cash equivalents, and marketable securities totaled $183.3 million as of December 31, 2024, providing an expected cash runway to the end of 2026. Net loss for the year ended December 31, 2024, was $58.7 million, compared to $69.0 million for the year ended December 31, 2023. Research and development expenses were $58.5 million for the year ended December 31, 2024, compared to $55.9 million for the year ended December 31, 2023.